Conjugated estrogens combined with bazedoxifene: The first approved tissue selective estrogen complex therapy

Expert Review of Clinical Pharmacology

Volumn 7, Issue 3, 2014, Pages 281-291

  Sharifi, Maryam ^a   Lewiecki, E Michael ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

Bazedoxifene; Estrogen; Menopause; Osteoporosis; Vasomotor symptoms

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE DENSITY; BONE TURNOVER; DRUG APPROVAL; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ESTROGEN THERAPY; GENERAL CONDITION IMPROVEMENT; HIP; HOT FLUSH; HUMAN; LUMBAR SPINE; MENOPAUSAL SYNDROME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RADIUS; REVIEW; TREATMENT RESPONSE; VAGINA ATROPHY; VAGINAL DRYNESS; VASOMOTOR DISORDER; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECTS; FEMALE; MENOPAUSE; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

BONE DENSITY; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 84898866887     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.893819     Document Type: Review

References (76)

1. Santoro N. Symptoms of menopause: hot flushes. Clin Obstet Gynecol 2008;51(3): 539-48
2. Avis ND, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345-56
3. Tella SH, Gallagher JC, et al. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause. Expert Opin Pharmacother 2013;14(17):2407-20
4. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996;11: 1043-51
5. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73
6. Shen W, Chen J, Punyanitya M, et al. MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. Osteoporos Int 2007;18(5):641-7
7. Hedlund LR, Gallagher JC, Meeger C, Stoner S. Change in vertebral shape in spinal osteoporosis. Calcif Tissue Int 1989; 44(3):168-72
8. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353(9152):571-80
9. Guglielmi G, Scalzo G. Imaging tools transform diagnosis of osteoporosis. Diagn Imaging Eur 2010;26:7-11
10. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women' s Health Initiative randomized controlled trial. JAMA 2004;14:1701-12
11. Writing group for the Women's Health Initiative Investigators: risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288: 321-33
12. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290(13):1729-38
13. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post stopping phases of the women's health initiative randomized trials. JAMA 2013;310:13-1353-68
14. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012;345:e6409
15. Powles TJ. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1999;91(8):730
16. Barakat RR. The effect of tamoxifen on the endometrium. Oncology (Williston Park) 1995;9(2):129-34
17. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - results from a 3-year randomized clinical trial. JAMA 1999;282(7):637-45
18. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295(23): 2727-41
19. Gruber C, Gruber D. Bazedoxifene (Wyeth). Curr Opin Investig Drugs 2004; 5(10):1086-93
20. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY- 140424) for clinical evaluation. Ann NY Acad. Sci 2001;949:317-26
21. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146(9): 3999-4008
22. Smith SY, Minck D, Jolette J, et al. Bazedoxifene prevents ovariectomy-induced bone loss in the cynomolgus monkeys. J Bone Miner Res 2005;20(Suppl 1):S174
23. Patat A, Mckeand W, Baird-bellaire S, et al. Absolute/relative bioavailabilty of bazedoxifene acetate in healthy postmenopausal women. Clin Pharmacol Ther 2003;73(2):P43
24. Chandrasekaran A, McKeand WE, Sullivan P, et al. Bazedoxifene acetate metabolic disposition in healthy, postmenopausal women. Clin Pharmacol Ther 2003;73(2):P47
25. Ermer J, Mckeand W, Sullivan P, et al. Bazedoxifene acetate dose proportionality in healthy, postmenopausal women. Clin Pharmacol Ther 2007;73(2):P46
26. Ermer JC, Kotake A, MC WE, et al. Clinical pharmacology of a novel tissue selective estrogen (WAY-140424) in postmenopausal women following administration for 30 days. J Bone Miner Res 2000;15(Suppl 1):S436
27. Ermer J, McKeand W, Sullivan P, et al. Bazedoxifene acetate dose proportionality in healthy postmenopausal women. Clin Pharmacol Ther 2003;73:46
28. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105(6):1397-404
29. Boudes P, Ronkin S, Korner S, et al. Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain. Osteoporos Int 2003;14(Suppl 7):S14
30. Lewiecki EM. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert Opin Investig Drugs 2007;16(10):1663-72
31. Ronkin S, Clarke L, Boudes P, Constantine G. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion. J Bone Miner Res 2001;16(Suppl 1):S413
32. Miller PD, Chines AA, Christiansen C, et al. Effects of Bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-35
33. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placeboand active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
34. North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012;19:257-71
35. Archer DF. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. Drugs Aging 2010;27:533-44
36. Pinkerton JV, Komm BS, Mirkin S. Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model. Climacteric 2013;16:1-11
37. Pfizer. DUAVEE Prescribing Information 2013. Available from: http://labeling.pfizer. com/ShowLabeling.aspx?id=1174 [Last accessed 30 December] [2013]
38. Kulak J Jr, Ferriani RA, Komm BS, Taylor HS. Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells. Reprod Sci 2013;20: 129-37
39. Oliva P, Roncoroni C, Radaelli E, et al. Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation. Reprod Sci 2013;20:119-28
40. Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas 2013;76:213-20
41. Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897-903
42. Ethun KF, Wood CE, Cline JM, et al. Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model. Menopause 2013;20(7):777-84
43. Song Y, Santen RJ, Wang JP, Yue W. Inhibitory effects of a bazedoxifene/ conjugated equine estrogen combination on human breast cancer cells in vitro. Endocrinology 2012;154:656-65
44. Wardell SE, Kazmin D, McDonnell DP. Research resource: transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. Mol Endocrinol 2012;26:1235-48
45. Song Y, Santen RJ, Wang JP, Yue W. Effects of the conjugated equine estrogen/ bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice. Endocrinology 2012;153:5706-15
46. Ethun KF, Wood CE, Register TC, et al. Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. Menopause 2012;19:1242-52
47. Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 2011;80:610-20
48. Kharode Y, Bodine PV, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084-91
49. Komm BS, Vlasseros F, Samadfam R, et al. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone 2011;49:376-86
50. Stovall DW, Utian WH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14: 510-17
51. Davis SR, O'Neill SM, Eden J, et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium - a pilot study. Menopause 2004;11:167-75
52. Carranza-Lira S, Gooch AL, Saldivar N, Osterwalder MS. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fertil Womens Med 2007;52:93-6
53. Dey M, Lyttle CR, Pickar JH. Recent insights into the varying activity of estrogens. Maturitas 2000;34(Suppl 2): S25-33
54. Campagnoli C, Ambroggio S, Biglia N, Sismondi P. Conjugated estrogens and breast cancer risk. Gynecol Endocrinol 1999;13(Suppl 6):13-19
55. Archer D, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/ CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-44
56. Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52
57. Lobo RA, Pinkerton JV, Gass M L, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-38
58. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/ conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24
59. Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/ conjugated estrogens. Menopause 2013;20: 138-45
60. Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116-24
61. Yu H, Racketa J, Chines AA, Mirkin S. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women. Climacteric 2013;16:252-7
62. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
63. Ayers B, Hunter MS. Health-related quality of life of women with menopausal hot flushes and night sweats. Climacteric 2013;16:235-9
64. Pinkerton JV, Chines A, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women. Menopause 2010;17:1237-8
65. Utian W, Yu H, Bobula J, et al. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-35
66. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL- Intervention questionnaire. Maturitas 2005;50:209-21
67. Hill CD, Fehnel SE, Bobula JD, et al. Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ). Menopause 2007;14:1047-55
68. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13:132-40
69. Kagan R, Williams RS, Pan K, et al. A randomized, placebo and active controlled trial of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281-9
70. Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/ conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92(3):1018-24
71. Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013; 16(3):338-46
72. Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 2013;121(5):959-68
73. Kagan R. The tissue selective estrogen complex. a novel approach to the treatment of menopausal symptoms. J Women's Health (Larchmt) 2012;21:975-81
74. Rossini M, Lello S, Sblendorio I, et al. Profile of bazedoxifene/ conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture. Drug Des Devel Ther 2013;7:601-10
75. Gatti D, Rossini M, Sblendorio I, Lello S. Pharmacokinetic evaluation of bazedoxifene for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol 2013;9(7): 883-92
76. Taylor HS, Ohleth K. Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review. Menopause 2012;19(4):479-85